UA115010C2 - Застосування фармацевтичної композиції для профілактики та лікування хвороб, обумовлених підвищеним рівнем індуцибельної синтази оксиду азоту - Google Patents

Застосування фармацевтичної композиції для профілактики та лікування хвороб, обумовлених підвищеним рівнем індуцибельної синтази оксиду азоту

Info

Publication number
UA115010C2
UA115010C2 UAA201611303A UAA201611303A UA115010C2 UA 115010 C2 UA115010 C2 UA 115010C2 UA A201611303 A UAA201611303 A UA A201611303A UA A201611303 A UAA201611303 A UA A201611303A UA 115010 C2 UA115010 C2 UA 115010C2
Authority
UA
Ukraine
Prior art keywords
treatment
elevated
prevention
pharmaceutical composition
nitric oxide
Prior art date
Application number
UAA201611303A
Other languages
English (en)
Inventor
Ліга Звєйнієцє
Майя Дамброва
Грігорій Вєінбєрг
Максімс Ворона
Іварс Калвін
Original Assignee
Акцію Сабєдріба "Олайнфарм"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акцію Сабєдріба "Олайнфарм" filed Critical Акцію Сабєдріба "Олайнфарм"
Publication of UA115010C2 publication Critical patent/UA115010C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Винахід належить до нового медичного застосування (4R)-2-(4-феніл-2-оксопіролідин-1-іл)ацетаміду для лікування патологічних станів, що характеризуються надекспресією гена iNOS, викликаних сепсисом або периферичною невропатією.
UAA201611303A 2014-05-14 2015-05-14 Застосування фармацевтичної композиції для профілактики та лікування хвороб, обумовлених підвищеним рівнем індуцибельної синтази оксиду азоту UA115010C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-14-39A LV15072B (lv) 2014-05-14 2014-05-14 Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
PCT/IB2015/053554 WO2015173763A1 (en) 2014-05-14 2015-05-14 Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase

Publications (1)

Publication Number Publication Date
UA115010C2 true UA115010C2 (uk) 2017-08-28

Family

ID=53716523

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611303A UA115010C2 (uk) 2014-05-14 2015-05-14 Застосування фармацевтичної композиції для профілактики та лікування хвороб, обумовлених підвищеним рівнем індуцибельної синтази оксиду азоту

Country Status (7)

Country Link
US (1) US20180064687A1 (uk)
EP (1) EP3142662B1 (uk)
EA (1) EA030563B1 (uk)
GE (1) GEP20186888B (uk)
LV (1) LV15072B (uk)
UA (1) UA115010C2 (uk)
WO (1) WO2015173763A1 (uk)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV13630B (en) 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除

Also Published As

Publication number Publication date
EA030563B1 (ru) 2018-08-31
EP3142662B1 (en) 2020-07-08
LV15072B (lv) 2016-09-20
US20180064687A1 (en) 2018-03-08
EA201692221A1 (ru) 2017-05-31
GEP20186888B (en) 2018-08-27
EP3142662A1 (en) 2017-03-22
WO2015173763A1 (en) 2015-11-19
LV15072A (lv) 2015-11-20

Similar Documents

Publication Publication Date Title
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
MX2023008693A (es) Polinucleotidos moduladores.
TW201613901A (en) New compounds
MX2017007976A (es) Compuestos inhibidores de parg.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2017013556A (es) Compuestos novedosos.
WO2015085318A3 (en) Targeted adaptive vaccines
WO2016011306A3 (en) Terminal modifications of polynucleotides
MX2017007478A (es) Compuestos inhibidores.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
SI3615014T1 (sl) Topična farmacevtska sestava, ki obsega vsaj amitriptilin, za zdravljenje periferne nevropatske bolečine
HK1256042A1 (zh) 用於治療糖尿病周圍神經病變的hdac抑制劑
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2018003563A (es) Nuevos compuestos.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
MX2017009608A (es) Compuestos anticancerigenos.
MD20180049A2 (ro) Compoziţie farmaceutică
MX2017013879A (es) Composiciones que comprenden anakinra.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity